Key result
Recombinant tissue-plasminogen activator (rtPA) combined with hirudin induced rapid, dose-dependent lysis of FeCl3-produced occlusive thrombi and recanalisation within 1 hour in mouse dorsal skinfold chambers.
Answers are grounded in this paper and cite their sources.
Although intravital microscopy models of thrombosis in mice have contributed to dissect the mechanisms of thrombus formation and stability, they have not been well adapted to study long-term evolution of occlusive thrombi. Here, we assessed the suitability of the dorsal skinfold chamber (DSC) for the study of thrombolysis and testing of thrombolytic agents by intravital microscopy. We show that induction of FeCl3-induced occlusive thrombosis is achievable in microvessels of DSCs, and that thrombi formed in DSCs can be visualised by intravital microscopy using brightfield transmitted light, or fluorescent staining of thrombus components such as fibrinogen, platelets, leukocytes, and von Willebrand factor. Direct application of control saline or recombinant tissue-plasminogen activator (rtPA) to FeCl3-produced thrombi in DSCs did not affect thrombus size or induce recanalisation. However, in the presence of hirudin, rtPA treatment caused a rapid dose-dependent lysis of occlusive thrombi, resulting in recanalisation within 1 hour after treatment. Skin haemorrhage originating from vessels located inside and outside the FeCl3-injured area was also observed in DSCs of rtPA-treated mice. We further show that rtPA-induced thrombolysis was enhanced in plasminogen activator inhibitor-1-deficient (PAI-1-/-) mice, and dropped considerably as the time between occlusion and treatment application increased. Together, our results show that by allowing visualization and measurement of thrombus lysis and potential bleeding complications of thrombolytic treatments, the DSC provides a model for studying endogenous fibrinolysis and for first-line screening of thrombolytic agents. Furthermore, using this system, we found that thrombin and clot aging impair the thrombolytic action of rtPA towards FeCl3-produced thrombi.
No takes yet. Share an insight, caveat, or question.
Rouzaud et al. (2012) studied FeCl3-induced occlusive thrombosis. Recombinant tissue-plasminogen activator (rtPA) with hirudin vs. Control saline or rtPA alone was evaluated on Thrombus lysis and microvascular recanalisation. Recombinant tissue-plasminogen activator (rtPA) combined with hirudin induced rapid, dose-dependent lysis of FeCl3-produced occlusive thrombi and recanalisation within 1 hour in mouse dorsal skinfold chambers.
Synapse has enriched 10 related papers. Consider them for comparative context: